Reviewer's report

**Title:** Phase II Study of the Combination Carboplatin plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients

**Version:** 4 **Date:** 6 April 2011

**Reviewer:** Maurie Markman

**Reviewer's report:**

While the limited sample size of this report is acknowledged, it is difficult to accept the statement that there is no difference in the activity of this regimen in the platinum-resistant from the platinum-sensitive populations when the percentage response rate are 16% (3 of 19 patients) versus 41% (9 of 22 patients). Comment.

What is the evidence the response rate of 16% makes this regimen particularly attractive for further study in ovarian cancer?

**Level of interest:** An article of limited interest

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests